A study to evaluate a new treatment for acyclovir-resistant HSV infections in immunocompromised subjects.

Home > A study to evaluate a new treatment for acyclovir-resistant HSV infections in immunocompromised subjects.

Are you struggling with HSV infections?

CLICK HERE FOR MORE INFORMATION:

The Study

  • A study to evaluate the safety of Pritelivir for HSV infections in immunocompromised subjects.

Study Benefits

  • Development of an oral medication (Pritelivir) for the oral treatment of acyclovir-resistant HSV infections in immunocompromised adults
  • Appropriate treatment is needed to stop viral replication and promote lesion healing
  • Study medication can potentially promote lesion healing
  • Study related care and medication are provided at no cost to the subject

Study Volunteers Must Meet the Following Criteria

  • Males or females
  • Ages 16 and above
  • Immunocompromised patient

Study Participant Expectations

  • 90-day study duration
  • 28-day treatment period (or until complete lesion healing is reached)
  • 7 total clinic visits (home visits are possible)
  • 2 follow up phone call visits

Cost

  • There is no cost to participate.
  • Patients who qualify may be compensated for time and travel

Register for a Study